JP2001163777A - Skin lotion - Google Patents

Skin lotion

Info

Publication number
JP2001163777A
JP2001163777A JP2000293405A JP2000293405A JP2001163777A JP 2001163777 A JP2001163777 A JP 2001163777A JP 2000293405 A JP2000293405 A JP 2000293405A JP 2000293405 A JP2000293405 A JP 2000293405A JP 2001163777 A JP2001163777 A JP 2001163777A
Authority
JP
Japan
Prior art keywords
weight
skin
urea
lidocaine
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000293405A
Other languages
Japanese (ja)
Other versions
JP3723728B2 (en
Inventor
Sahoe Tsunoda
佐保枝 角田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Priority to JP2000293405A priority Critical patent/JP3723728B2/en
Publication of JP2001163777A publication Critical patent/JP2001163777A/en
Application granted granted Critical
Publication of JP3723728B2 publication Critical patent/JP3723728B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROBLEM TO BE SOLVED: To prepare a skin lotion causing only a little skin irritation, preventing liquid drops in its application and excellent in sense of use. SOLUTION: This skin lotion consists of (1) 8-23 wt.% of urea, (2) 0.3-4 wt.% of diphenhydramine or its salt, (3) 0.5-5 wt.% of lidocaine, (4) 20-32 wt.% of a lower alcohol, (5) 0.1-20 wt.% of a humectant, (6) 0.1-2 wt.% of a thickener and (7) the remainder of water, and is useful as a therapeutic agent for dry skin diseases.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、角質水分保持機能
及び鎮痒作用を合わせもつ使用感の優れた皮膚外用液剤
に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a solution for external use on the skin which has a keratin water retention function and an antipruritic effect and has an excellent feeling upon use.

【0002】[0002]

【従来の技術】乾燥性皮膚疾患は、高齢化に伴う老人性
乾皮症をはじめ、アトピー性皮膚炎など近年増加傾向に
ある疾患のひとつである。この疾患は、加齢やその他の
原因により皮膚機能が低下し、皮脂分泌量や皮膚血流量
が減少することによって起こる。乾燥した皮膚は、わず
かな刺激や外界の温度変化等によって、激しいかゆみを
生じるため、患部を無意識にかきむしり、掻破部分に炎
症が生じて、更に皮膚の症状を悪化させる。また、激し
いかゆみによって、不眠やイライラが起こり、精神的な
不安に悩まされる。これらのことより、乾燥性皮膚疾患
には、乾燥した皮膚の水分保持能を高めると共に、そう
痒感を抑えることが治療上必要である。
2. Description of the Related Art Dry skin diseases are one of the diseases which have been increasing in recent years, such as senile xeroderma associated with aging and atopic dermatitis. The disease is caused by decreased skin function due to aging and other causes, resulting in decreased sebum secretion and cutaneous blood flow. Dry skin is severely itchy due to slight irritation or a change in the temperature of the outside world, so that the affected area is unconsciously scraped, inflammation occurs at the scratched part, and the skin condition is further worsened. In addition, severe itching causes insomnia and irritation, and suffers from mental anxiety. From these facts, it is therapeutically necessary for dry skin diseases to increase the water retention ability of dry skin and to suppress itching.

【0003】そこで、角質の水分保持機能を高める尿素
と鎮痒作用をもつ抗ヒスタミン剤及び局所麻酔剤を含有
し、アルコールを多く含んだ皮膚外用液剤が知られてい
る(特開平3−291221号公報)。また、同様に尿
素とジフェンヒドラミン及びリドカインを含有し、アル
コール量を減らして乳剤とした皮膚疾患治療乳剤が知ら
れている(特開平7−291856号公報)。
[0003] Therefore, there is known a skin external preparation containing a large amount of alcohol containing urea which enhances the water retention function of the stratum corneum, an antihistamine having an antipruritic effect, and a local anesthetic (JP-A-3-291221). Similarly, there is known a skin disease treatment emulsion containing urea, diphenhydramine and lidocaine, and reducing the amount of alcohol to prepare an emulsion (Japanese Patent Application Laid-Open No. 7-291856).

【0004】[0004]

【発明が解決しようとする課題】特開平3−29122
1号公報に記載された液剤は、低級アルコールを多く含
有するため、掻破部分への皮膚刺激が大きかった。ま
た、粘性のない液剤のため、手の平にとった液剤を患部
に塗布するまでにこぼしてしまい、使いやすい製剤とは
いえなかった。特開平7−291856号公報は、低級
アルコールの含有量を減らして皮膚刺激を小さくし、ジ
フェンヒドラミン及びリドカインの経皮吸収量を増加さ
せた。また薬物を均一に分散させるために乳剤とし、液
だれ防止及び乳化の安定を目的として増粘剤を添加し
た。しかしながら、増粘剤を加えた乳剤は塗付時のべた
つきが大きいため、広範囲に塗付するには不向きであ
る。そこで、皮膚刺激が小さく、塗布時の液ダレを防止
し、かつ使用感の優れた液剤が求められていた。
Problems to be Solved by the Invention
The liquid preparation described in Japanese Patent Publication No. 1 contains a large amount of lower alcohol, so that skin irritation to the scratched portion was large. In addition, since the liquid preparation had no viscosity, the liquid preparation taken on the palm spilled before being applied to the affected area, and it could not be said that the preparation was easy to use. JP-A-7-291856 has reduced the content of lower alcohol to reduce skin irritation and increased the percutaneous absorption of diphenhydramine and lidocaine. An emulsion was prepared to uniformly disperse the drug, and a thickener was added for the purpose of preventing dripping and stabilizing the emulsion. However, an emulsion containing a thickener has a large stickiness at the time of application, and is not suitable for application over a wide range. Therefore, there has been a demand for a liquid preparation which has a small skin irritation, prevents liquid dripping at the time of application, and has an excellent feeling upon use.

【0005】[0005]

【課題を解決するための手段】このような状況下、本発
明者らは、使用感、例えば、肌触りが良く、べたつき感
の少ない、かつ塗付時の液ダレを防止した液剤について
鋭意検討した結果、尿素、8〜23重量%、ジフェ
ンヒドラミン又はその塩、0.3〜4重量%、リドカ
イン、0.5〜5重量%、低級アルコール、20〜3
2重量%、保湿剤、0.1〜20重量%、増粘剤、
0.1〜2重量%、水、残部からなる液剤が、皮膚刺
激が小さく、使用感が良好で、塗布時に液ダレの少ない
透明な皮膚外用液剤であることを見出し、本発明を完成
するに至った。
Under these circumstances, the inventors of the present invention have intensively studied a liquid agent which has a feeling of use, for example, a good touch, a low stickiness, and which prevents liquid dripping at the time of application. As a result, urea, 8 to 23% by weight, diphenhydramine or a salt thereof, 0.3 to 4% by weight, lidocaine, 0.5 to 5% by weight, lower alcohol, 20 to 3
2% by weight, humectant, 0.1-20% by weight, thickener,
It has been found that a liquid preparation comprising 0.1 to 2% by weight, water and the balance is a transparent liquid preparation for external use with minimal skin irritation, good usability, and little dripping when applied. Reached.

【0006】以下に、本発明を詳細に説明する。本発明
液剤は、尿素を配合する。尿素は、角質の水分保持作用
を有するため、乾燥性皮膚疾患の薬効成分として用いら
れており、8〜23重量%、好ましくは10〜20重量
%配合することにより、充分な治療効果が得られる。
Hereinafter, the present invention will be described in detail. The solution of the present invention contains urea. Since urea has a keratin water retention effect, it is used as a medicinal ingredient for dry skin diseases, and a sufficient therapeutic effect can be obtained by adding 8 to 23% by weight, preferably 10 to 20% by weight. .

【0007】本発明液剤は、ジフェンヒドラミン又はそ
の塩酸塩、タンニン酸塩等の薬理的に許容される塩等を
配合する。その配合量は、0.3〜4重量%、好ましく
は0.5〜2重量%である。また、本発明液剤は、リド
カインを配合する。その配合量は、0.5〜5重量%、
好ましくは1〜3重量%である。
[0007] The liquid preparation of the present invention contains diphenhydramine or a pharmaceutically acceptable salt thereof such as a hydrochloride or a tannate thereof. The compounding amount is 0.3 to 4% by weight, preferably 0.5 to 2% by weight. Further, the liquid preparation of the present invention contains lidocaine. The compounding amount is 0.5 to 5% by weight,
Preferably, it is 1 to 3% by weight.

【0008】本発明で用いられる低級アルコールとして
は、エタノール及び/又はイソプロパノールが挙げら
れ、配合量は20〜32重量%、好ましくは25〜30
重量%である。この範囲の配合量であれば、適度な使用
感を有する液剤となる。
The lower alcohol used in the present invention includes ethanol and / or isopropanol, and the compounding amount is 20 to 32% by weight, preferably 25 to 30% by weight.
% By weight. When the amount is within this range, the liquid preparation has an appropriate feeling of use.

【0009】保湿剤は、従来公知に使用されるものであ
れば特に限定されないが、例えばグリセリン、プロピレ
ングリコール、1,3−ブチレングリコール、ポリエチ
レングリコール200、ポリエチレングリコール30
0、ポリエチレングリコール400等の多価アルコール
類や乳酸、乳酸ナトリウム等が挙げられ、これらを1種
または2種以上配合することができる。配合量は保湿剤
の種類により若干異なるが、0.1〜20重量%、好ま
しくは5〜20重量%である。
The humectant is not particularly limited as long as it is conventionally known. Examples thereof include glycerin, propylene glycol, 1,3-butylene glycol, polyethylene glycol 200 and polyethylene glycol 30.
0, polyhydric alcohols such as polyethylene glycol 400, lactic acid, sodium lactate, etc., and one or more of these can be blended. The compounding amount is slightly different depending on the kind of the humectant, but is 0.1 to 20% by weight, preferably 5 to 20% by weight.

【0010】本発明で用いられる増粘剤としては、ポリ
ビニルピロリドン、又はヒドロキシプロピルセルロース
及びヒドロキシプロピルメチルセルロース等のセルロー
ス誘導体等の水溶性高分子物質が挙げられる。好ましく
は、ヒドロキシプロピルメチルセルロース等のセルロー
ス誘導体である。最も好ましくは、ヒドロキシプロピル
メチルセルロースである。配合量は0.1〜2重量%、
好ましくは0.2〜1重量%である。
Examples of the thickener used in the present invention include water-soluble polymer substances such as polyvinylpyrrolidone and cellulose derivatives such as hydroxypropylcellulose and hydroxypropylmethylcellulose. Preferably, it is a cellulose derivative such as hydroxypropylmethylcellulose. Most preferably, it is hydroxypropyl methylcellulose. The compounding amount is 0.1 to 2% by weight,
Preferably it is 0.2 to 1% by weight.

【0011】本発明の皮膚外用液剤は、上記成分以外に
必要に応じて、他の薬効成分、例えば、カンフル、サリ
チル酸、グリチルレチン酸、グリチルリチン酸二カリウ
ム等の消炎剤、メントール、ハッカ油等の清涼剤、酢酸
トコフェロール等のビタミン剤、クロタミトン等の鎮痒
剤を配合できる。また、pH調整剤として、水酸化ナト
リウム、トリエタノールアミン、塩酸、乳酸等;防腐剤
として、パラオキシ安息香酸メチル、パラオキシ安息香
酸プロピル等;香料として、ユーカリ油等;界面活性剤
として、ポリオキシエチレン硬化ヒマシ油、セスキオレ
イン酸ソルビタン等;溶解補助剤として、乳酸、塩酸等
を適宜配合することもできる。
The external preparation for skin of the present invention may contain, if necessary, other medicinal ingredients in addition to the above-mentioned components, such as anti-inflammatory agents such as camphor, salicylic acid, glycyrrhetinic acid and dipotassium glycyrrhizinate, and cooling agents such as menthol and peppermint oil. Agents, vitamins such as tocopherol acetate, and antipruritic agents such as crotamiton. Also, as a pH adjuster, sodium hydroxide, triethanolamine, hydrochloric acid, lactic acid, etc .; as a preservative, methyl paraoxybenzoate, propyl paraoxybenzoate, etc .; as a fragrance, eucalyptus oil, etc .; Hardened castor oil, sorbitan sesquioleate, and the like; lactic acid, hydrochloric acid, and the like can be appropriately added as a solubilizing agent.

【0012】本発明の皮膚外用液剤の好ましい組成は、
尿素、10〜20重量%、ジフェンヒドラミン又は
その塩、0.5〜2重量%、リドカイン、1〜3重量
%、エタノール及び/又はイソプロパノール25〜3
0重量%、保湿剤、5〜20重量%、増粘剤、0.
2〜1重量%、水、残部である。
A preferred composition of the external preparation for skin of the present invention is:
Urea, 10 to 20% by weight, diphenhydramine or a salt thereof, 0.5 to 2% by weight, lidocaine, 1 to 3% by weight, ethanol and / or isopropanol 25 to 3
0% by weight, humectant, 5-20% by weight, thickener, 0.1%
2 to 1% by weight, water and the balance.

【0013】このようにして調製された本発明液剤は、
適当な容器に充填して製品とされ、適宜患部に塗付する
ことにより、適用される。本発明の皮膚外用液剤は、通
常公知の方法で製造できるが、例えば、 水に増粘剤を溶解する。 低級アルコール、水にリドカイン、ジフェンヒドラミ
ン又はその塩、尿素、保湿剤等を溶解する。 にを加えて撹拌することで、本発明の液剤を製造
することができる。上記のように製造された、本発明皮
膚外用液剤の形状は、pH5.0〜6.0で、透明であ
る。
The liquid preparation of the present invention thus prepared is
The product is filled into a suitable container to form a product, and is applied by appropriately applying to the affected part. The solution for external use on the skin of the present invention can be produced by a generally known method. For example, a thickener is dissolved in water. Dissolve lidocaine, diphenhydramine or its salt, urea, humectant, etc. in lower alcohol and water. , And the mixture is stirred, whereby the liquid preparation of the present invention can be produced. The external preparation for skin of the present invention produced as described above is transparent at pH 5.0 to 6.0.

【0014】[0014]

【実施例】以下に本発明を実施例に従って説明するが、
本発明は、これらに限定されるものではない。
EXAMPLES The present invention will be described below with reference to Examples.
The present invention is not limited to these.

【0015】 実施例1 尿素 10.0(重量%) 塩酸ジフェンヒドラミン 1.0 リドカイン 2.0 酢酸トコフェロール 0.3 エタノール 20.0 ポリエチレングリコール400 10.0 乳酸ナトリウム 5.0 ヒドロキシプロピルメチルセルロース 0.25 乳酸 1.5 ポリオキシエチレン硬化ヒマシ油60 3.0 パラオキシ安息香酸メチル 0.05 パラオキシ安息香酸プロピル 0.025 水 残部 上記各成分を溶解し、pH5.5の透明な液剤を得た。Example 1 Urea 10.0 (wt%) Diphenhydramine hydrochloride 1.0 Lidocaine 2.0 Tocopherol acetate 0.3 Ethanol 20.0 Polyethylene glycol 400 10.0 Sodium lactate 5.0 Hydroxypropyl methylcellulose 0.25 Lactic acid 1.5 Polyoxyethylene hydrogenated castor oil 60 3.0 Methyl paraoxybenzoate 0.05 Propyl paraoxybenzoate 0.025 Water Remainder The above components were dissolved to obtain a transparent liquid of pH 5.5.

【0016】 実施例2 尿素 10.0(重量%) 塩酸ジフェンヒドラミン 1.0 リドカイン 2.0 酢酸トコフェロール 0.3 エタノール 26.8 ポリエチレングリコール400 10.0 乳酸ナトリウム 5.0 ヒドロキシプロピルメチルセルロース 0.25 乳酸 1.6 ポリオキシエチレン硬化ヒマシ油60 3.0 パラオキシ安息香酸メチル 0.05 パラオキシ安息香酸プロピル 0.025 水 残部 上記各成分を溶解し、pH5.7の透明な液剤を得た。Example 2 Urea 10.0 (% by weight) Diphenhydramine hydrochloride 1.0 Lidocaine 2.0 Tocopherol acetate 0.3 Ethanol 26.8 Polyethylene glycol 400 10.0 Sodium lactate 5.0 Hydroxypropyl methylcellulose 0.25 Lactic acid 1.6 Polyoxyethylene hydrogenated castor oil 60 3.0 Methyl paraoxybenzoate 0.05 Propyl paraoxybenzoate 0.025 Water Remainder The above components were dissolved to obtain a transparent solution having a pH of 5.7.

【0017】 実施例3 尿素 10.0(重量%) 塩酸ジフェンヒドラミン 1.0 リドカイン 2.0 酢酸トコフェロール 0.3 エタノール 32.0 ポリエチレングリコール400 10.0 乳酸ナトリウム 5.0 ヒドロキシプロピルメチルセルロース 0.25 乳酸 1.5 ポリオキシエチレン硬化ヒマシ油60 3.0 パラオキシ安息香酸メチル 0.05 パラオキシ安息香酸プロピル 0.025 水 残部 上記各成分を溶解し、pH5.8の透明な液剤を得た。Example 3 Urea 10.0 (wt%) Diphenhydramine hydrochloride 1.0 Lidocaine 2.0 Tocopherol acetate 0.3 Ethanol 32.0 Polyethylene glycol 400 10.0 Sodium lactate 5.0 Hydroxypropyl methylcellulose 0.25 Lactic acid 1.5 Polyoxyethylene hydrogenated castor oil 60 3.0 Methyl paraoxybenzoate 0.05 Propyl paraoxybenzoate 0.025 Water Remainder The above components were dissolved to obtain a transparent liquid having a pH of 5.8.

【0018】 実施例4 尿素 10.0(重量%) 塩酸ジフェンヒドラミン 1.0 リドカイン 2.0 酢酸トコフェロール 0.3 エタノール 26.9 グリセリン 10.0 乳酸ナトリウム 5.0 ヒドロキシプロピルメチルセルロース 0.25 乳酸 1.5 ポリオキシエチレン硬化ヒマシ油60 3.0 パラオキシ安息香酸メチル 0.05 パラオキシ安息香酸プロピル 0.025 水 残部 上記各成分を溶解し、pH5.5の透明な液剤を得た。Example 4 Urea 10.0 (wt%) Diphenhydramine hydrochloride 1.0 Lidocaine 2.0 Tocopherol acetate 0.3 Ethanol 26.9 Glycerin 10.0 Sodium lactate 5.0 Hydroxypropyl methylcellulose 0.25 Lactic acid 1. 5 Polyoxyethylene hydrogenated castor oil 60 3.0 Methyl paraoxybenzoate 0.05 Propyl paraoxybenzoate 0.025 Water Remainder The above components were dissolved to obtain a transparent liquid of pH 5.5.

【0019】 実施例5 尿素 10.0(重量%) 塩酸ジフェンヒドラミン 1.0 リドカイン 2.0 酢酸トコフェロール 0.3 イソプロパノール 25.0 ポリエチレングリコール400 10.0 乳酸ナトリウム 5.0 ヒドロキシプロピルメチルセルロース 0.25 乳酸 1.5 ポリオキシエチレン硬化ヒマシ油60 3.0 パラオキシ安息香酸メチル 0.05 パラオキシ安息香酸プロピル 0.025 水 残部 上記各成分を溶解し、pH5.7の透明な液剤を得た。Example 5 Urea 10.0 (wt%) Diphenhydramine hydrochloride 1.0 Lidocaine 2.0 Tocopherol acetate 0.3 Isopropanol 25.0 Polyethylene glycol 400 10.0 Sodium lactate 5.0 Hydroxypropyl methylcellulose 0.25 Lactic acid 1.5 Polyoxyethylene hydrogenated castor oil 60 3.0 Methyl paraoxybenzoate 0.05 Propyl paraoxybenzoate 0.025 Water Remainder The above components were dissolved to obtain a transparent solution having a pH of 5.7.

【0020】[0020]

【試験例1】本発明の外用液剤の使用感を評価する目的
で、実施例2および尿素含有製剤である市販品A(液
剤)、市販品B(乳剤)のべたつき感、液ダレのしにく
さ及び全体的な使用しやすさを、以下のような評価軸を
使用し、男性6名、女性5名、計11名のアンケートで
比較検討した。
Test Example 1 In order to evaluate the feeling of use of the liquid preparation for external use of the present invention, Example 2 and the urea-containing preparations, commercially available product A (solution) and commercially available product B (emulsion), had a sticky feeling and a dripping effect. The stiffness and overall ease of use were compared and examined using questionnaires of a total of 11 men, 6 men and 5 women, using the following evaluation axes.

【0021】 評価項目 実施例2 市販品A(液剤) 市販品B(乳剤) べたつき感 3.3 2.8 3.0 液ダレ 3.5 2.4 4.0 全体的な使いやすさ 4.0 3.0 3.6Evaluation Items Example 2 Commercial Product A (Liquid) Commercial Product B (Emulsion) Stickiness 3.3 2.8 3.0 Liquid Sag 3.5 2.4 4.0 Overall Ease of Use 4. 0 3.0 3.6

【0022】上記の平均評価点より、実施例2は市販品
2剤と比較して、べたつき感が少ないことがわかった。
また、液ダレの評価結果は乳剤である市販品Bが最も高
かったものの、全体的な使いやすさでは液剤である実施
例2が最も優れていた。以上のことから、本発明の液剤
は、べたつき感の少ない、塗布時の液ダレを少なくした
使いやすい皮膚外用液剤であるといえる。
From the above average evaluation points, it was found that Example 2 had less stickiness than the two commercial products.
In addition, the evaluation result of liquid dripping was the highest for the commercial product B as an emulsion, but Example 2 which was a liquid agent was the most excellent in overall ease of use. From the above, it can be said that the liquid preparation of the present invention is an easy-to-use liquid preparation for external use on the skin with less stickiness and less dripping during application.

【0023】[0023]

【効果】以上の結果より明らかなように、本発明の外用
液剤は、優れた皮膚水分保持機能を有し、かつ塗布時の
液だれが少なく、べたつき感の小さい使いやすい乾燥性
皮膚疾患治療剤である。
[Effects] As is clear from the above results, the external preparation of the present invention has an excellent skin moisture retention function, has little dripping when applied, and has an easy-to-use agent for treating dry skin diseases with a small sticky feeling. It is.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 17/04 A61P 17/04 17/16 17/16 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 17/04 A61P 17/04 17/16 17/16

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】尿素、8〜23重量% ジフェンヒドラミン又はその塩、0.3〜4重量% リドカイン、0.5〜5重量% 低級アルコール、20〜32重量% 保湿剤、0.1〜20重量% 増粘剤、0.1〜2重量% 水、残部 からなる皮膚外用液剤。1. Urea, 8 to 23% by weight diphenhydramine or a salt thereof, 0.3 to 4% by weight lidocaine, 0.5 to 5% by weight lower alcohol, 20 to 32% by weight humectant, 0.1 to 20% by weight % Thickener, 0.1-2% by weight water, balance
JP2000293405A 1999-09-30 2000-09-27 Skin topical solution Expired - Fee Related JP3723728B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000293405A JP3723728B2 (en) 1999-09-30 2000-09-27 Skin topical solution

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11-279670 1999-09-30
JP27967099 1999-09-30
JP2000293405A JP3723728B2 (en) 1999-09-30 2000-09-27 Skin topical solution

Publications (2)

Publication Number Publication Date
JP2001163777A true JP2001163777A (en) 2001-06-19
JP3723728B2 JP3723728B2 (en) 2005-12-07

Family

ID=26553426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000293405A Expired - Fee Related JP3723728B2 (en) 1999-09-30 2000-09-27 Skin topical solution

Country Status (1)

Country Link
JP (1) JP3723728B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112909A1 (en) * 2004-05-24 2005-12-01 Dojin Iyaku-Kako Co., Ltd. Anti-inflammatory analgesic external aqueous liquid preparation
WO2008058681A1 (en) 2006-11-17 2008-05-22 Beiersdorf Ag Cosmetic formulation containing glucosyl glycerides and urea
JP2009280511A (en) * 2008-05-20 2009-12-03 Otsuka Pharmaceut Factory Inc Antipruritic agent for external use
JP5008162B1 (en) * 2011-06-02 2012-08-22 株式会社 資生堂 Scalp Kayumi improvement composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03291221A (en) * 1989-07-27 1991-12-20 Otsuka Pharmaceut Factory Inc Liquid for external use for skin
JPH07291856A (en) * 1994-04-28 1995-11-07 Yuutoku Yakuhin Kogyo Kk Therapeutic emulsion for dermatosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03291221A (en) * 1989-07-27 1991-12-20 Otsuka Pharmaceut Factory Inc Liquid for external use for skin
JPH07291856A (en) * 1994-04-28 1995-11-07 Yuutoku Yakuhin Kogyo Kk Therapeutic emulsion for dermatosis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112909A1 (en) * 2004-05-24 2005-12-01 Dojin Iyaku-Kako Co., Ltd. Anti-inflammatory analgesic external aqueous liquid preparation
WO2008058681A1 (en) 2006-11-17 2008-05-22 Beiersdorf Ag Cosmetic formulation containing glucosyl glycerides and urea
JP2009280511A (en) * 2008-05-20 2009-12-03 Otsuka Pharmaceut Factory Inc Antipruritic agent for external use
JP5008162B1 (en) * 2011-06-02 2012-08-22 株式会社 資生堂 Scalp Kayumi improvement composition
JP2012250928A (en) * 2011-06-02 2012-12-20 Shiseido Co Ltd Composition for ameliorating pruritus of scalp

Also Published As

Publication number Publication date
JP3723728B2 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
JP3487633B2 (en) Skin disease treatment emulsion
JP4549006B2 (en) Gel ointment
JP5052558B2 (en) Gel ointment
JPH0338524A (en) Corticosteroid-containing lotion agent
JP2002212107A (en) Topical application composition
US20200197379A1 (en) Composition for preventing or treating atopic dermatitis
JP2529571B2 (en) Skin irritation suppressant and cosmetics containing the same
CA1095413A (en) Preparation for prevention and treatment of acne vulgaris and use of pyridine aldehydes for the prevention and treatment of acne vulgaris
JPH03291221A (en) Liquid for external use for skin
JPH0899889A (en) Therapeutic agent for atopic dermatitis
JP3723728B2 (en) Skin topical solution
US6365200B1 (en) Topical skin sensitizer
JPH11246329A (en) Skin preparation for external use
JP2000198719A (en) Hair growing agent
JP3798927B2 (en) Blood circulation promoting topical skin preparation
EP0048280A1 (en) Skin and nail composition containing phosphate-trialkanolamine complex
KR20020013248A (en) Hydrogel Preparation of Lidocaine Microemulsion for the Treatment of Premature Ejaculation
JP3575033B2 (en) External preparation
JP2020158493A (en) Water-in-oil type (w/o type) cream containing panthenol
JP2000198718A5 (en)
JP2003012501A (en) Antipruritic aerosol preparation
JP3427445B2 (en) Cream
JP3418201B2 (en) External preparation for skin ▲ so ▼ pruritus
JPH111433A (en) Tolnaftate-containing liquid agent
JP2828185B2 (en) Bath composition

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050215

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050916

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090922

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090922

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090922

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100922

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100922

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110922

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110922

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120922

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120922

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120922

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130922

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130922

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees